Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 100.29 Million USD | -2.26% |
| 2023 | 106.48 Million USD | 7.88% |
| 2022 | 98.7 Million USD | 99.28% |
| 2021 | 49.53 Million USD | -21.8% |
| 2020 | 63.34 Million USD | -5.85% |
| 2019 | 67.27 Million USD | 13.27% |
| 2018 | 59.39 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 100.48 Million USD | -6.29% |
| 2024 Q2 | 110.61 Million USD | 0.0% |
| 2024 Q1 | 110.61 Million USD | 4.3% |
| 2024 Q4 | 102.43 Million USD | 0.0% |
| 2024 FY | 100.29 Million USD | -5.81% |
| 2023 Q2 | 101.98 Million USD | 1.44% |
| 2023 Q1 | 100.53 Million USD | 1.86% |
| 2023 FY | 106.48 Million USD | 7.88% |
| 2023 Q4 | 102.86 Million USD | -0.79% |
| 2023 Q3 | 103.68 Million USD | 1.67% |
| 2022 FY | 98.7 Million USD | 99.28% |
| 2022 Q3 | 96.69 Million USD | 2.34% |
| 2022 Q4 | 98.7 Million USD | 2.07% |
| 2022 Q1 | 50.2 Million USD | 1.37% |
| 2022 Q2 | 94.48 Million USD | 88.18% |
| 2021 Q2 | 55.59 Million USD | -11.95% |
| 2021 Q1 | 63.14 Million USD | -0.31% |
| 2021 FY | 49.53 Million USD | -21.8% |
| 2021 Q4 | 49.53 Million USD | 6.92% |
| 2021 Q3 | 46.32 Million USD | -16.68% |
| 2020 Q3 | 65.71 Million USD | -9.58% |
| 2020 Q4 | 63.34 Million USD | -3.61% |
| 2020 FY | 63.34 Million USD | -5.85% |
| 2020 Q1 | 68.79 Million USD | 2.26% |
| 2020 Q2 | 72.67 Million USD | 5.64% |
| 2019 Q1 | 61.15 Million USD | 2.97% |
| 2019 Q4 | 67.27 Million USD | -4.19% |
| 2019 Q2 | 60.38 Million USD | -1.26% |
| 2019 Q3 | 70.21 Million USD | 16.28% |
| 2019 FY | 67.27 Million USD | 13.27% |
| 2018 FY | 59.39 Million USD | 0.0% |
| 2018 Q4 | 59.39 Million USD | 89.03% |
| 2018 Q3 | 31.42 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | -100.0% |
| 2014 Q2 | 233 Thousand USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -1253586.6% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -5613.251% |
| Qrons Inc. | 80 Thousand USD | -125268.66% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | -393.772% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -58473.222% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | -379.673% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -170929.174% |
| Marizyme, Inc. | 667.12 Thousand USD | -14933.813% |
| Genus plc | 228.2 Million USD | 56.05% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 166.1 Million USD | 39.62% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -1819474.165% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -4438.232% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -7048.941% |
| IMV Inc. | 27.39 Million USD | -266.059% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -1748.25% |
| MultiCell Technologies, Inc. | 36.43 USD | -275308513.78% |
| ONE Bio Corp. | 592.19 Thousand USD | -16836.046% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 55.61 Million USD | -80.348% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -4405.612% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -8064.939% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -17984.518% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -396338.31% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -5182.94% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -31047.493% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.108% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -66763.285% |
| Enzolytics Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -60979.095% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | -553.217% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -2250683.842% |
| Genscript Biotech Corporation | 287.12 Million USD | 65.07% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -79308.82% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -43641.328% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 229.69 Thousand USD | -43565.154% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | -1113.637% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -37656.669% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -9426115.038% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -66935.791% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -66935.791% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | 141 Thousand USD | -71031.155% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -1182.55% |
| SYBLEU INC | 300 Thousand USD | -33331.643% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -27076.588% |
| International Stem Cell Corporation | 445 Thousand USD | -22438.186% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | -1130.613% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -21846.374% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -8538.667% |
| PureTech Health plc | 18.25 Million USD | -449.561% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -66763.285% |
| IXICO plc | 275 Thousand USD | -36370.883% |
| IntelGenx Technologies Corp. | 11.83 Million USD | -747.157% |
| Gelesis Holdings, Inc. | 26.3 Million USD | -281.219% |
| CSL Limited | 11.23 Billion USD | 99.108% |
| Cellectis S.A. | 36.21 Million USD | -176.973% |